罗格列酮,临床注释,变异和临床注释数据

罗格列酮

临床注释ID

1451257285

药物名称(英)

rosiglitazone

变异单倍型

CYP2C8*1, CYP2C8*3

基因

CYP2C8

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Efficacy

表现型类别

功效

分数

4.5

PMID计数

计数的证据

表现型

表现型(英)

最新日期

2021-12-03

URL

https://www.pharmgkb.org/clinicalAnnotation/1451257285

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
74	*3	Patients with the CYP2C83 allele in combination with 1 or another 3 allele may have decreased response to rosiglitazone as compared to patients with the CYP2C81/*1 genotype. Other genetic and clinical factors may also influence the response to rosiglitazone.
73	*1	Patients with the CYP2C81 allele in combination with another 1 allele may have increased response to rosiglitazone as compared to patients with one or two copies of the *3 allele. Other genetic and clinical factors may also influence the response to rosiglitazone.

临床证据

id	证据的ID	总结
14682	1451604160	CYP2C8 3 is not associated with glucose lowering when treated with rosiglitazone in healthy individuals as compared to CYP2C8 1.
14681	1450935044	CYP2C8 *3 is associated with decreased mean absolute difference in HbA1c when treated with rosiglitazone in people with Diabetes Mellitus, Type 2.
14680	1448276377	CYP2C8 3 is associated with decreased response to rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 1/*1.

临床病史

id	类型	评论
228	Update	Added efficacy phenotype category. Consolidated VAs from PMID 17178266.
227	Update	Migrate to CYP2C8 core allele *1
226	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
225	Create	Created

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:33068302000535
　医药代理商群１：

医药代理商群２：

医药代理商群３：